Two Sigma Securities’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-48,700
Closed -$2.5M 2942
2022
Q2
$2.5M Sell
48,700
-28,700
-37% -$1.49M 0.09% 254
2022
Q1
$5.7M Buy
77,400
+75,600
+4,200% +$6.74M 0.2% 105
2021
Q4
$258K Sell
1,800
-5,600
-76% -$962K 0.01% 908
2021
Q3
$1.53M Buy
7,400
+5,200
+236% +$1.15M 0.05% 359
2021
Q2
$467K Buy
+2,200
New +$403K 0.01% 695

Other funds holding NVAX

Two Sigma Securities's NVAX Position: Q2 2026 in Review

Two Sigma Securities reduced its Novavax (NVAX) stake by 24% in Q2 2026, selling an estimated $29.7K and leaving 10,323 shares worth $97.2K. The position accounts for 0.01% of the portfolio, ranked #1305.

Two Sigma Securities first reported a position in NVAX in Q3 2016 and has held it in 12 quarters since. The position peaked at $1.36M in Q1 2022. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Two Sigma Securities held 10,323 shares of Novavax worth $97.2K as of Q2 2026.
  • Two Sigma Securities sold 3,316 Novavax shares in Q2 2026, an estimated $29.7K.
  • Novavax made up 0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1305 holding.
  • Two Sigma Securities first reported a position in Novavax in Q3 2016 and has held it in 12 quarters since.
  • Two Sigma Securities's Novavax position peaked at $1.36M in Q1 2022.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.